CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation
- PMID: 38677657
- DOI: 10.1016/j.nbd.2024.106516
CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation
Abstract
Hyperphosphorylated TAR DNA-binding protein 43 (TDP-43) aggregates in the cytoplasm of neurons is the neuropathological hallmark of amyotrophic lateral sclerosis (ALS) and a group of neurodegenerative diseases collectively referred to as TDP-43 proteinopathies that includes frontotemporal dementia, Alzheimer's disease, and limbic onset age-related TDP-43 encephalopathy. The mechanism of TDP-43 phosphorylation is poorly understood. Previously we reported casein kinase 1 epsilon gene (CSNK1E gene encoding CK1ε protein) as being tightly correlated with phosphorylated TDP-43 (pTDP-43) pathology. Here we pursued studies to investigate in cellular models and in vitro how CK1ε and CK1δ (a closely related family sub-member) mediate TDP-43 phosphorylation in disease. We first validated the binding interaction between TDP-43 and either CK1δ and CK1ε using kinase activity assays and predictive bioinformatic database. We utilized novel inducible cellular models that generated translocated phosphorylated TDP-43 (pTDP-43) and cytoplasmic aggregation. Reducing CK1 kinase activity with siRNA or small molecule chemical inhibitors resulted in significant reduction of pTDP-43, in both soluble and insoluble protein fractions. We also established CK1δ and CK1ε are the primary kinases that phosphorylate TDP-43 compared to CK2α, CDC7, ERK1/2, p38α/MAPK14, and TTBK1, other identified kinases that have been implicated in TDP-43 phosphorylation. Throughout our studies, we were careful to examine both the soluble and insoluble TDP-43 protein fractions, the critical protein fractions related to protein aggregation diseases. These results identify CK1s as critical kinases involved in TDP-43 hyperphosphorylation and aggregation in cellular models and in vitro, and in turn are potential therapeutic targets by way of CK1δ/ε inhibitors.
Keywords: Amyotrophic lateral sclerosis; Casein kinase 1 delta; Casein kinase 1 epsilon; Phosphorylation; TAR DNA-binding protein (TDP-43); TDP-43 proteinopathies.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no competing interests.
Similar articles
-
CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis.Acta Neuropathol Commun. 2024 Dec 4;12(1):187. doi: 10.1186/s40478-024-01902-z. Acta Neuropathol Commun. 2024. PMID: 39633494 Free PMC article.
-
Detection of pTDP-43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis.Brain Pathol. 2024 Nov;34(6):e13261. doi: 10.1111/bpa.13261. Epub 2024 Apr 11. Brain Pathol. 2024. PMID: 38602336 Free PMC article.
-
Neuronal TDP-43 aggregation drives changes in microglial morphology prior to immunophenotype in amyotrophic lateral sclerosis.Acta Neuropathol Commun. 2025 Feb 21;13(1):39. doi: 10.1186/s40478-025-01941-0. Acta Neuropathol Commun. 2025. PMID: 39985110 Free PMC article.
-
TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis.BMC Neurol. 2018 Jun 28;18(1):90. doi: 10.1186/s12883-018-1091-7. BMC Neurol. 2018. PMID: 29954341 Free PMC article.
-
TARDBP-Related Amyotrophic Lateral Sclerosis-Frontotemporal Dementia.2009 Apr 23 [updated 2023 Jan 5]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2009 Apr 23 [updated 2023 Jan 5]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301761 Free Books & Documents. Review.
Cited by
-
CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis.Acta Neuropathol Commun. 2024 Dec 4;12(1):187. doi: 10.1186/s40478-024-01902-z. Acta Neuropathol Commun. 2024. PMID: 39633494 Free PMC article.
-
Amyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2).Int J Mol Sci. 2025 May 29;26(11):5240. doi: 10.3390/ijms26115240. Int J Mol Sci. 2025. PMID: 40508048 Free PMC article. Review.
-
Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy.Cell Rep. 2025 Jan 28;44(1):115205. doi: 10.1016/j.celrep.2024.115205. Epub 2025 Jan 14. Cell Rep. 2025. PMID: 39817908 Free PMC article.
-
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration.Mol Neurodegener. 2025 May 8;20(1):53. doi: 10.1186/s13024-025-00839-8. Mol Neurodegener. 2025. PMID: 40340943 Free PMC article. Review.
-
Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases.Int J Mol Sci. 2024 Sep 23;25(18):10187. doi: 10.3390/ijms251810187. Int J Mol Sci. 2024. PMID: 39337671 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous